You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

ALTOPREV Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Altoprev, and what generic alternatives are available?

Altoprev is a drug marketed by Covis and is included in one NDA.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Altoprev

A generic version of ALTOPREV was approved as lovastatin by ACTAVIS ELIZABETH on December 17th, 2001.

  Try a Trial

Drug patent expirations by year for ALTOPREV
Drug Prices for ALTOPREV

See drug prices for ALTOPREV

Recent Clinical Trials for ALTOPREV

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AmgenPhase 4
Brigham and Women's HospitalPhase 4
Autoimmunity Centers of ExcellencePhase 2

See all ALTOPREV clinical trials

Pharmacology for ALTOPREV

US Patents and Regulatory Information for ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 DISCN No No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ALTOPREV

See the table below for patents covering ALTOPREV around the world.

Country Patent Number Title Estimated Expiration
Japan 5132721 ⤷  Try a Trial
Canada 2390301 ⤷  Try a Trial
United Kingdom 2371748 HMG-COA reductase inhibitor extended release formulation ⤷  Try a Trial
Canada 2315329 PREPARATION AMELIOREE D'INHIBITEURS DE LA HMG COA REDUCTASE A LIBERATION ETENDUE (IMPROVED HMG COA REDUCTASE INHIBITOR EXTENDED RELEASE FORMULATION) ⤷  Try a Trial
Canada 2586240 ⤷  Try a Trial
Japan 2002508311 ⤷  Try a Trial
Australia 1360701 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.